OS Therapies (OSTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OSTX OS Therapies

Watchlist

3.750
-0.420-10.07%

Close Sep 10 16:00 ET

3.950
+0.200+5.33%

Post 20:02 ET

78.32MMarket Cap-11942P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
Yahoo FinanceSep 5 08:22 ET
EF Hutton Initiates OS Therapies(OSTX.US) With Buy Rating, Announces Target Price $21
Moomoo NewsSep 4 06:31 ET · Ratings
Express News | Os Therapies Announces Last Patient Enrolled in Ost-Her2 Osteosarcoma Phase 2B Clinical Trial Receives Last Treatment Dose
ReutersAug 29 07:53 ET
Paul Romness Discusses OS Therapies' IPO & Clinical Advancement | NYSE-A:OSTX
Proactive InvestorsAug 28 07:51 ET
The Investing Authority to Host Breakout Session With OS Therapies LIVE on X
AccesswireAug 27 10:00 ET
Brookline Capital Initiates OS Therapies(OSTX.US) With Buy Rating, Announces Target Price $9
Moomoo NewsAug 22 13:32 ET · Ratings

Comments

Jaguar8

Aug 29 06:53

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...